Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eczema drug dupilumab shows promise in skin of color patients

NCT ID NCT05590585

Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested the drug dupilumab (Dupixent) in 124 adolescents and adults with darker skin tones who have moderate-to-severe eczema. Participants received injections every two weeks for 24 weeks. The goal was to see if the drug safely improves skin symptoms and quality of life in this specific group. Results showed that many patients achieved significant skin clearance.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dupilumab (Dupixent)
What this could lead to
If successful, this study could confirm that dupilumab works well for people with darker skin tones, leading to better treatment options for eczema in this group.
What could go wrong
This is a small, single-arm study without a placebo group, so results may not be definitive. Side effects like injection reactions or eye inflammation are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

124 people

The number who actually took part.

Started

Jan 2023

Finished

Nov 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: 1. Skin of color, defined as Fitzpatrick skin type ≥4 at screening visit 2. Diagnosis of moderate-to-severe atopic dermatitis (AD) that cannot be adequately controlled with topical AD medications, as defined in protocol 3. Has applied a stable dose of topical emollient (moisturizer) twice daily as per physician recommendation starting at screening visit Key Exclusion Criteria: 1. Self-reported Caucasian or White race 2. Adolescent body weight less than 30 kg at screening 3. Prior use of dupilumab within 6 months of screening 4. Concomitant skin diseases or other pigmentary disorder that could confound AD assessments 5. Current or prior use, within 12 weeks before the screening visit, of phototherapy or tanning beds 6. Active helminthic infections; suspected or high risk of helminthic infection, unless clinical and (if necessary) laboratory assessments have ruled out active infection before baseline 7. Treatment with topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI) within 7 days prior to baseline 8. Planned or anticipated use of any prohibited medications and procedures, as defined in protocol 9. Has received a COVID-19 vaccination within 1 week of planned start of study medication or for which the planned COVID-19 vaccinations would not be completed 1 week prior to start of study drug NOTE: Other Protocol Defined Inclusion / Exclusion Criteria Apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic eczema are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema Pruritus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic eczema Moderate-to-severe atopic dermatitis

Contacts and locations

Locations

  • Advanced Medical Research PC

    Atlanta, Georgia, 30328, United States

  • Atlanta Biomedical Clinical Research LLC

    Atlanta, Georgia, 30331, United States

  • C2 Research Center, LLC

    Montgomery, Alabama, 36117, United States

  • Callender Dermatology and Cosmetic Center

    Glenn Dale, Maryland, 20769, United States

  • Center for Clinical Studies, LTD.LLP

    Houston, Texas, 77004, United States

  • Center for Dermatology Clinical Research, inc.

    Fremont, California, 94538, United States

  • Century Research LLC

    Miami, Florida, 33173, United States

  • Dermatology and Skin Cancer Specialists, LLC dba US Dermatology Partners

    Rockville, Maryland, 20850, United States

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

  • Heights Dermatology & Aesthetic Center - Heights Location

    Houston, Texas, 77008, United States

  • Markowitz Medical

    New York, New York, 10128, United States

  • NYC Health + Hospital , Elmhurst Hospital Center

    Elmhurst, New York, 11373, United States

  • National Allergy and Asthma Research, LLC.

    North Charleston, South Carolina, 29420, United States

  • Northwestern Memorial Hospital

    Chicago, Illinois, 60611, United States

  • Oregon Health & Science University

    Portland, Oregon, 97239, United States

  • Philip Fried, MD PLLC

    The Bronx, New York, 10463, United States

  • RFSA Dermatology

    San Antonio, Texas, 78213, United States

  • Rao Dermatology

    Atlantic Highlands, New Jersey, 07716, United States

  • Revival Research Institute , LLC

    Troy, Michigan, 48084, United States

  • SF Research Institute

    San Francisco, California, 94127, United States

  • SUNY Downstate Medical Center

    Brooklyn, New York, 11203, United States

  • Skin and Cancer Associates, LLP

    Miami, Florida, 33137, United States

  • Texas Dermatology and Laser Specialists

    San Antonio, Texas, 78218, United States

  • The University Of Alabama At Birmingham

    Birmingham, Alabama, 35233, United States

  • Total Skin & Beauty Dermatology Center

    Birmingham, Alabama, 35203, United States

  • UCSD/ Rady Children's Hospital

    San Diego, California, 92123, United States

  • UCSF

    San Francisco, California, 94118, United States

  • University of Miami Miller School of Medicine

    Miami, Florida, 33136, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

  • Wayne State University Physician Group Dermatology

    Dearborn, Michigan, 48126, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.